Dabigatran etexilate ( DrugBank: Dabigatran etexilate, Dabigatran )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	1
75	クッシング病	1

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02426229 (ClinicalTrials.gov)	February 2016	4/3/2015	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Scleroderma;Interstitial Lung Disease	Drug: dabigatran etexilate	Medical University of South Carolina	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	18 Years	70 Years	All	15	Phase 1	United States

75. クッシング病

---

臨床試験数 : 205 /  薬物数 : 176 - (DrugBank : 45) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05347979 (ClinicalTrials.gov)	May 25, 2022	18/4/2022	Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants	An Open-Label, Drug-Drug Interaction Study Designed to Evaluate the Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Subjects	Cushing Syndrome;Neoplasms	Drug: Dabigatran Etexilate;Drug: Relacorilant	Corcept Therapeutics	NULL	Completed	18 Years	55 Years	All	30	Phase 1	United States